Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tina Nova, Rick Klausner, Paul Menter

Premium

Illumina has named Tina Nova as the senior vice president and general manager of its oncology business. Nova replaces Rick Klausner, who has served as interim oncology leader since January. Klauner will continue to serve as senior vice president and chief medical officer, Illumina said.

Nova is the co-founder of Genoptix and previously served as the firm's president and CEO. She also co-founded Nanogen, where she was COO and president. Nova holds a BSc in biological sciences from the University of California, Irvine and a PhD in biochemistry from the University of California, Riverside.


Paul Menter has joined SomaLogic as vice president and general manager of its life science tools business.

Menter most recently served as general manager of Bioseparations at Thermo Fisher Scientific. Before that, he was division manager of lab separations and of North American sales and service at Bio-Rad Laboratories.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.